Skip to main content
. 2005 Oct 8;55(8):958–968. doi: 10.1007/s00262-005-0084-8

Fig. 2.

Fig. 2

Recognition of autologous (a) or allogeneic HLA-A/-B compatible (b) melanoma lines by PBMCs of vaccinated patients. PBMCs were obtained from the blood of each patient before (V2) and after (V6 or 7) treatment and tested by IFN-γ-ELISPOT assay. Gray columns indicate statistically significant differences at P< 0.05